Based on these results, the 2023 ESMO Clinical Practice Guidelines (v2.0) now recommend PD-1 inhibitors combined with trastuzumab and chemotherapy as the preferred first-line regimen for HER2-positive metastatic disease (5), which has also been incorporated into the Pan-Asian adapted ESMO Clinical Practice Guidelines for standardized management of gastric cancer patients across Asian regions (6). The gene discussed is ERBB2; the disease is gastric cancer.